BTBP: Tiantan Kunming has been approved to conduct clinical trials for "human fibrinogen"
I'm PortAI, I can summarize articles.
BTBP announced that its subsidiary TianTan Kunming has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen." This product must complete clinical trials, submit a market application, and pass relevant reviews and approval processes before it can be produced and sold on the market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments